Last €0.09 EUR
Change Today +0.001 / 1.10%
Volume 0.0
As of 2:08 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

nexgenrx inc (N5I) Snapshot

Open
€0.09
Previous Close
€0.09
Day High
€0.09
Day Low
€0.09
52 Week High
03/14/14 - €0.14
52 Week Low
12/4/14 - €0.07
Market Cap
5.1M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
55.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEXGENRX INC (N5I)

Related News

No related news articles were found.

nexgenrx inc (N5I) Related Businessweek News

No Related Businessweek News Found

nexgenrx inc (N5I) Details

NexgenRx Inc. provides administration and health benefit claims adjudication services in Canada. It administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers. The company’s services include prescription drug claims adjudication; dental claims adjudication; and claims adjudication for extended health benefits, including paramedical services, such as chiropractors, podiatrists, and massage therapists. It also provides retrospective and prospective claims data analysis; individual and aggregate stop loss products; emergency out of province/country travel benefits; and medical concierge services. The company offers its services to various organizations who manage health benefit plans on behalf of various plan sponsors, as well as directly to Canadian plan sponsors who wish to provide an administrative services only health benefit plan to their plan members. NexgenRx Inc. was founded in 2003 and is headquartered in Toronto, Canada.

Founded in 2003

nexgenrx inc (N5I) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$165.0K
Interim Chief Financial Officer
Total Annual Compensation: C$90.0K
Compensation as of Fiscal Year 2013.

nexgenrx inc (N5I) Key Developments

NexgenRx, Inc. Announces Earnings Results for the Third Quarter Ended September 30, 2014

NexgenRx, Inc. announced earnings results for the third quarter ended September 30, 2014. For the third quarter ended September 30, 2014 transaction and administration revenue was $1,015,336, generating gross profit of $794,106 and a net loss of $172,510.

NexgenRx, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2014

NexgenRx, Inc. reported earnings results for the second quarter ended June 30, 2014. For the second quarter, transaction and administration revenue was $1,074,973, generating gross profit of $856,626 and a net loss of $114,531.

NexgenRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2014

NexgenRx, Inc. reported earnings results for the first quarter ended March 31, 2014. For the first quarter ended March 31, 2014 transaction and administration revenue was $1,034,006 and a net loss was $58,500.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
N5I:GR €0.09 EUR +0.001

N5I Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for N5I.
View Industry Companies
 

Industry Analysis

N5I

Industry Average

Valuation N5I Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEXGENRX INC, please visit www.nexgenrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.